A man with cold agglutinin disease (CAD) successfully underwent microvascular free tissue transfer — a tissue and blood vessel transplant — to repair extensive damage to his face, a case study reported. Authors noted that due to the lack of precedence in the literature, this report provides guidance on…
News
Enjaymo (sutimlimab) quickly led to increases in hemoglobin and lowered the need for blood transfusions in four women with cold agglutinin disease (CAD), in whom the treatment remained safe and effective for about three years, according to data from a Phase 1 open-label extension trial. Trial data was…
Long-term treatment with Sanofi’s Enjaymo (sutimlimab-jome) safely and effectively prevented red blood cell destruction (hemolysis), anemia, and the need for blood transfusions, while improving the quality of life in adults with primary cold agglutinin disease (CAD). That’s according to 2.5 years of data from the Phase 3…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
An elderly woman in Japan is the first reported patient in Asia to develop cold agglutinin disease (CAD) due to COVID-19, according to a new case study. The patient was found to have anemia, or an unusually low red blood cell count, that was not resolved with a blood…
A 71-year-old woman with primary cold agglutinin disease (CAD) was successfully treated with the glucocorticoid prednisone, a case study reported. Its scientists noted that primary CAD typically does not respond to glucocorticoids, but in particular instances like this case, it can. The study, “A Case of Idiopathic Cold…
The case of a man with cold agglutinin disease (CAD) that was found to be secondary to a blood cancer, called diffuse large B-cell lymphoma (DLBCL), was described in a recent report. The researcher proposes that DLBCL should be considered as a potential diagnosis in people with unexplained CAD.
Treatment with Soliris (eculizumab) eased the symptoms of cold agglutinin disease (CAD) in a man in France who possibly developed the condition as a result of a severe infection with SARS-CoV-2, the virus that causes COVID-19, a case study reports. While the patient ultimately died, the researchers said the study’s findings…
The case of a man with cold agglutinin disease (CAD) co-occurring with a blood cell disorder called myelodysplastic syndrome was described in a recent report from India. The report, “Cold autoimmune hemolytic anemia with myelodysplastic syndrome: Not just an ‘Open and Shut case,” was published in…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Recent Posts
- After a trip to the ER, I’m figuring out how to strengthen my immune system
- Study finds inherited thrombophilia screening not needed in AIHA
- For US woman, CAD exacerbates iron disorder, leading to liver damage
- Post-exertional malaise leads to a cycle of crashes and comebacks
- Enjaymo provides lasting CAD control even with fewer doses: Study
- Being vigilant during transfusions brings me a vital victory
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD